Report cover image

Global Topical Drugs CDMO Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20359983

Description

Summary

According to APO Research, the global Topical Drugs CDMO market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Topical Drugs CDMO market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Topical Drugs CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Topical Drugs CDMO market include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Topical Drugs CDMO, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Topical Drugs CDMO, also provides the value of main regions and countries. Of the upcoming market potential for Topical Drugs CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Topical Drugs CDMO revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Topical Drugs CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Topical Drugs CDMO company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Topical Drugs CDMO Segment by Company

Piramal Pharma Solutions
Pierre Fabre Group
PCI Pharma Services
MedPharm Ltd.
Lubrizol Life Science
DPT Laboratories LTD.
Contract Pharmaceuticals Limited
Cambrex Corporation
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Topical Drugs CDMO Segment by Type

Contract Development
Contract Manufacturing
Topical Drugs CDMO Segment by Application

Semi-Solid Formulations
Solid Formulations
Liquid Formulations
Others
Topical Drugs CDMO Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Topical Drugs CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Topical Drugs CDMO key companies, revenue, market share, and recent developments.
3. To split the Topical Drugs CDMO breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Topical Drugs CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Topical Drugs CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Topical Drugs CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Topical Drugs CDMO industry.
Chapter 3: Detailed analysis of Topical Drugs CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Topical Drugs CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Topical Drugs CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Topical Drugs CDMO Market Size, 2020 VS 2024 VS 2031
1.3 Global Topical Drugs CDMO Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Topical Drugs CDMO Market Dynamics
2.1 Topical Drugs CDMO Industry Trends
2.2 Topical Drugs CDMO Industry Drivers
2.3 Topical Drugs CDMO Industry Opportunities and Challenges
2.4 Topical Drugs CDMO Industry Restraints
3 Topical Drugs CDMO Market by Company
3.1 Global Topical Drugs CDMO Company Revenue Ranking in 2024
3.2 Global Topical Drugs CDMO Revenue by Company (2020-2025)
3.3 Global Topical Drugs CDMO Company Ranking (2023-2025)
3.4 Global Topical Drugs CDMO Company Manufacturing Base and Headquarters
3.5 Global Topical Drugs CDMO Company Product Type and Application
3.6 Global Topical Drugs CDMO Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Topical Drugs CDMO Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Topical Drugs CDMO Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Topical Drugs CDMO Market by Type
4.1 Topical Drugs CDMO Type Introduction
4.1.1 Contract Development
4.1.2 Contract Manufacturing
4.2 Global Topical Drugs CDMO Sales Value by Type
4.2.1 Global Topical Drugs CDMO Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Topical Drugs CDMO Sales Value by Type (2020-2031)
4.2.3 Global Topical Drugs CDMO Sales Value Share by Type (2020-2031)
5 Topical Drugs CDMO Market by Application
5.1 Topical Drugs CDMO Application Introduction
5.1.1 Semi-Solid Formulations
5.1.2 Solid Formulations
5.1.3 Liquid Formulations
5.1.4 Others
5.2 Global Topical Drugs CDMO Sales Value by Application
5.2.1 Global Topical Drugs CDMO Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Topical Drugs CDMO Sales Value by Application (2020-2031)
5.2.3 Global Topical Drugs CDMO Sales Value Share by Application (2020-2031)
6 Topical Drugs CDMO Regional Value Analysis
6.1 Global Topical Drugs CDMO Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Topical Drugs CDMO Sales Value by Region (2020-2031)
6.2.1 Global Topical Drugs CDMO Sales Value by Region: 2020-2025
6.2.2 Global Topical Drugs CDMO Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Topical Drugs CDMO Sales Value (2020-2031)
6.3.2 North America Topical Drugs CDMO Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Topical Drugs CDMO Sales Value (2020-2031)
6.4.2 Europe Topical Drugs CDMO Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Topical Drugs CDMO Sales Value (2020-2031)
6.5.2 Asia-Pacific Topical Drugs CDMO Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Topical Drugs CDMO Sales Value (2020-2031)
6.6.2 South America Topical Drugs CDMO Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Topical Drugs CDMO Sales Value (2020-2031)
6.7.2 Middle East & Africa Topical Drugs CDMO Sales Value Share by Country, 2024 VS 2031
7 Topical Drugs CDMO Country-level Value Analysis
7.1 Global Topical Drugs CDMO Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Topical Drugs CDMO Sales Value by Country (2020-2031)
7.2.1 Global Topical Drugs CDMO Sales Value by Country (2020-2025)
7.2.2 Global Topical Drugs CDMO Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.3.2 USA Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.4.2 Canada Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.6.2 Germany Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.7.2 France Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.7.3 France Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.9.2 Italy Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.10.2 Spain Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.11.2 Russia Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.14.2 China Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.14.3 China Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.15.2 Japan Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.17.2 India Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.17.3 India Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.18.2 Australia Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.22.2 Chile Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.24.2 Peru Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.26.2 Israel Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.27.2 UAE Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.29.2 Iran Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Topical Drugs CDMO Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Topical Drugs CDMO Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Topical Drugs CDMO Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Piramal Pharma Solutions
8.1.1 Piramal Pharma Solutions Comapny Information
8.1.2 Piramal Pharma Solutions Business Overview
8.1.3 Piramal Pharma Solutions Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
8.1.5 Piramal Pharma Solutions Recent Developments
8.2 Pierre Fabre Group
8.2.1 Pierre Fabre Group Comapny Information
8.2.2 Pierre Fabre Group Business Overview
8.2.3 Pierre Fabre Group Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
8.2.5 Pierre Fabre Group Recent Developments
8.3 PCI Pharma Services
8.3.1 PCI Pharma Services Comapny Information
8.3.2 PCI Pharma Services Business Overview
8.3.3 PCI Pharma Services Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
8.3.5 PCI Pharma Services Recent Developments
8.4 MedPharm Ltd.
8.4.1 MedPharm Ltd. Comapny Information
8.4.2 MedPharm Ltd. Business Overview
8.4.3 MedPharm Ltd. Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
8.4.5 MedPharm Ltd. Recent Developments
8.5 Lubrizol Life Science
8.5.1 Lubrizol Life Science Comapny Information
8.5.2 Lubrizol Life Science Business Overview
8.5.3 Lubrizol Life Science Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
8.5.5 Lubrizol Life Science Recent Developments
8.6 DPT Laboratories LTD.
8.6.1 DPT Laboratories LTD. Comapny Information
8.6.2 DPT Laboratories LTD. Business Overview
8.6.3 DPT Laboratories LTD. Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
8.6.5 DPT Laboratories LTD. Recent Developments
8.7 Contract Pharmaceuticals Limited
8.7.1 Contract Pharmaceuticals Limited Comapny Information
8.7.2 Contract Pharmaceuticals Limited Business Overview
8.7.3 Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
8.7.5 Contract Pharmaceuticals Limited Recent Developments
8.8 Cambrex Corporation
8.8.1 Cambrex Corporation Comapny Information
8.8.2 Cambrex Corporation Business Overview
8.8.3 Cambrex Corporation Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
8.8.5 Cambrex Corporation Recent Developments
8.9 Bora Pharmaceutical CDMO
8.9.1 Bora Pharmaceutical CDMO Comapny Information
8.9.2 Bora Pharmaceutical CDMO Business Overview
8.9.3 Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
8.9.5 Bora Pharmaceutical CDMO Recent Developments
8.10 Ascendia Pharmaceuticals
8.10.1 Ascendia Pharmaceuticals Comapny Information
8.10.2 Ascendia Pharmaceuticals Business Overview
8.10.3 Ascendia Pharmaceuticals Topical Drugs CDMO Revenue and Gross Margin (2020-2025)
8.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
8.10.5 Ascendia Pharmaceuticals Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.